Indole-3-carbinol

Phase 3Small molecule

UUniversity of Kansas Medical Center

Indole-3-carbinol is one of 89 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

EndometriosisActive, not recruiting

Breast CancerPhase 1

Active, not recruiting

Prostate CancerPreclinical

Active, not recruiting

EndometriosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Indole-3-carbinol

UUniversity of Kansas Medical Center

Phase 3

1 3

MS Contin

Merck & Co.

Preclinical

2 4

Lexiscan

Astellas

Preclinical

1 5

Adenocard

Astellas

Preclinical

1 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 9

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 10

Tricor

JJagotec

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Endometriosis

NCT07164183

Clinical

Trials by Indication[1]

Endometriosis1 trial

Clinical Study to Compare Efficacy and Safety of Indinol Forto® 200 mg Capsules and Visanne 2 mg Tablets in Treatment of Endometriosis

Recruiting·AAlcea·Phase 3·NCT07164183·290 enrolled

Trial1 trial

Trial of Indole-3-Carbinol and Silibinin

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT03687073·21 enrolled

Prostate Cancer1 trial

Brassica Vegetables or Indole-3-Carbinol in Treating Patients With PSA Recurrence After Surgery for Prostate Cancer

Completed·VVanderbilt University·N/A·NCT00607932·66 enrolled

Cancer1 trial

Indole-3-Carbinol in Preventing Cancer in Healthy Participants

Completed·UUniversity of Kansas·Phase 1·NCT00100958

Breast Cancer1 trial

Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer

Completed·UUniversity of Kansas Medical Center·Phase 1·NCT00033345·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Indole-3-carbinol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Indole-3-carbinol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Indole-3-carbinol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Kansas Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Kansas Medical Center

Indole-3-carbinol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Endometriosis1 trial

Trial1 trial

Prostate Cancer1 trial

Cancer1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News